Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) Stock Competitors & Peer Comparison
See DMAQ's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Shell Companies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DMAQ and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DMAQ | $2.96 | -64.72% | 12.9M | -22.77 | -$0.13 | N/A |
| CCIV | $24.25 | +5.90% | 44.4B | N/A | N/A | N/A |
| PSACU | $17.08 | +0.35% | 12B | -108.79 | -$0.16 | N/A |
| RTPY | $9.91 | -0.30% | 11.6B | N/A | N/A | N/A |
| LVRAW | $0.04 | +0.00% | 11.5B | N/A | N/A | N/A |
| CMLFU | $13.00 | -4.55% | 10.3B | -1444.44 | -$0.01 | N/A |
| PSAC | $13.78 | -0.36% | 9.7B | N/A | N/A | N/A |
| GRSVU | $11.39 | +3.36% | 6.8B | N/A | N/A | N/A |
| APSG | $7.39 | -25.88% | 6.3B | 36.95 | $0.20 | N/A |
| RTP | $10.03 | -4.48% | 6.3B | N/A | N/A | N/A |
Stock Comparison
Lucid Group, Inc. (NYSE: CCIV)
DMAQ vs CCIV Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CCIV has a market cap of 44.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CCIV trades at $24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CCIV's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to CCIV's ROE of -2.94%. Regarding short-term risk, DMAQ is more volatile compared to CCIV. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CCIV's competition here
Property Solutions Acquisition Corp. (NASDAQ: PSACU)
DMAQ vs PSACU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, PSACU has a market cap of 12B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while PSACU trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas PSACU's P/E ratio is -108.79. In terms of profitability, DMAQ's ROE is -3.18%, compared to PSACU's ROE of -35.44%. Regarding short-term risk, DMAQ is more volatile compared to PSACU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check PSACU's competition here
Reinvent Technology Partners Y (NASDAQ: RTPY)
DMAQ vs RTPY Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, RTPY has a market cap of 11.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while RTPY trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas RTPY's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to RTPY's ROE of -0.40%. Regarding short-term risk, DMAQ is more volatile compared to RTPY. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check RTPY's competition here
Levere Holdings Corp. (NASDAQ: LVRAW)
DMAQ vs LVRAW Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, LVRAW has a market cap of 11.5B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while LVRAW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas LVRAW's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to LVRAW's ROE of N/A. Regarding short-term risk, DMAQ is more volatile compared to LVRAW. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check LVRAW's competition here
CM Life Sciences, Inc. (NASDAQ: CMLFU)
DMAQ vs CMLFU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CMLFU has a market cap of 10.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CMLFU trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CMLFU's P/E ratio is -1444.44. In terms of profitability, DMAQ's ROE is -3.18%, compared to CMLFU's ROE of -0.28%. Regarding short-term risk, DMAQ is more volatile compared to CMLFU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CMLFU's competition here
Property Solutions Acquisition Corp. (NASDAQ: PSAC)
DMAQ vs PSAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, PSAC has a market cap of 9.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while PSAC trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas PSAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to PSAC's ROE of -35.44%. Regarding short-term risk, DMAQ is more volatile compared to PSAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check PSAC's competition here
Gores Holdings V, Inc. (NASDAQ: GRSVU)
DMAQ vs GRSVU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GRSVU has a market cap of 6.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GRSVU trades at $11.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GRSVU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to GRSVU's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to GRSVU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GRSVU's competition here
Apollo Strategic Growth Capital (NYSE: APSG)
DMAQ vs APSG Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, APSG has a market cap of 6.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while APSG trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas APSG's P/E ratio is 36.95. In terms of profitability, DMAQ's ROE is -3.18%, compared to APSG's ROE of +0.06%. Regarding short-term risk, DMAQ is more volatile compared to APSG. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check APSG's competition here
Reinvent Technology Partners (NYSE: RTP)
DMAQ vs RTP Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, RTP has a market cap of 6.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while RTP trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas RTP's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to RTP's ROE of -0.74%. Regarding short-term risk, DMAQ is more volatile compared to RTP. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check RTP's competition here
Dragoneer Growth Opportunities Corp. (NYSE: DGNR)
DMAQ vs DGNR Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DGNR has a market cap of 5.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DGNR trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DGNR's P/E ratio is -308.67. In terms of profitability, DMAQ's ROE is -3.18%, compared to DGNR's ROE of +0.02%. Regarding short-term risk, DMAQ is more volatile compared to DGNR. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DGNR's competition here
VectoIQ Acquisition Corp. II (NASDAQ: VTIQ)
DMAQ vs VTIQ Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, VTIQ has a market cap of 5.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while VTIQ trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas VTIQ's P/E ratio is 91.50. In terms of profitability, DMAQ's ROE is -3.18%, compared to VTIQ's ROE of +472.81%. Regarding short-term risk, DMAQ is more volatile compared to VTIQ. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check VTIQ's competition here
VectoIQ Acquisition Corp. II (NASDAQ: VTIQU)
DMAQ vs VTIQU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, VTIQU has a market cap of 5.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while VTIQU trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas VTIQU's P/E ratio is 100.60. In terms of profitability, DMAQ's ROE is -3.18%, compared to VTIQU's ROE of +472.81%. Regarding short-term risk, DMAQ is more volatile compared to VTIQU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check VTIQU's competition here
Vector Acquisition Corporation (NASDAQ: VACQ)
DMAQ vs VACQ Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, VACQ has a market cap of 5.5B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while VACQ trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas VACQ's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to VACQ's ROE of -0.12%. Regarding short-term risk, DMAQ is more volatile compared to VACQ. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check VACQ's competition here
SVF Investment Corp. 3 (NASDAQ: SVFC)
DMAQ vs SVFC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SVFC has a market cap of 5.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SVFC trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SVFC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SVFC's ROE of -0.11%. Regarding short-term risk, DMAQ is more volatile compared to SVFC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SVFC's competition here
VG Acquisition Corp. (NYSE: VGAC)
DMAQ vs VGAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, VGAC has a market cap of 5B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while VGAC trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas VGAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to VGAC's ROE of -1.21%. Regarding short-term risk, DMAQ is more volatile compared to VGAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check VGAC's competition here
CM Life Sciences III Inc. (NASDAQ: CMLT)
DMAQ vs CMLT Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CMLT has a market cap of 4.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CMLT trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CMLT's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to CMLT's ROE of N/A. Regarding short-term risk, DMAQ is more volatile compared to CMLT. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CMLT's competition here
Gores Holdings VI, Inc. (NASDAQ: GHVI)
DMAQ vs GHVI Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GHVI has a market cap of 4.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GHVI trades at $14.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GHVI's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to GHVI's ROE of -1.28%. Regarding short-term risk, DMAQ is more volatile compared to GHVI. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GHVI's competition here
Nextdoor Holdings, Inc. (NASDAQ: KVSB)
DMAQ vs KVSB Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, KVSB has a market cap of 4.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while KVSB trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas KVSB's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to KVSB's ROE of -0.10%. Regarding short-term risk, DMAQ is more volatile compared to KVSB. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check KVSB's competition here
FTAC Olympus Acquisition Corp. (NASDAQ: FTOCU)
DMAQ vs FTOCU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FTOCU has a market cap of 4.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FTOCU trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FTOCU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FTOCU's ROE of +0.10%. Regarding short-term risk, DMAQ is more volatile compared to FTOCU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FTOCU's competition here
Tuscan Holdings Corp. (NASDAQ: THCBU)
DMAQ vs THCBU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, THCBU has a market cap of 3.9B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while THCBU trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas THCBU's P/E ratio is -101.87. In terms of profitability, DMAQ's ROE is -3.18%, compared to THCBU's ROE of -0.23%. Regarding short-term risk, DMAQ is more volatile compared to THCBU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check THCBU's competition here
Climate Change Crisis Real Impact I Acquisition Corporation (NYSE: CLII)
DMAQ vs CLII Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CLII has a market cap of 3.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CLII trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CLII's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to CLII's ROE of -0.25%. Regarding short-term risk, DMAQ is more volatile compared to CLII. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CLII's competition here
GreenVision Acquisition Corp. (NASDAQ: GRNV)
DMAQ vs GRNV Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GRNV has a market cap of 3.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GRNV trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GRNV's P/E ratio is -59.68. In terms of profitability, DMAQ's ROE is -3.18%, compared to GRNV's ROE of +0.05%. Regarding short-term risk, DMAQ is more volatile compared to GRNV. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GRNV's competition here
Forest Road Acquisition Corp. (NYSE: FRX)
DMAQ vs FRX Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FRX has a market cap of 3.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FRX trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FRX's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FRX's ROE of +0.19%. Regarding short-term risk, DMAQ is more volatile compared to FRX. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FRX's competition here
Holicity Inc. (NASDAQ: HOLUU)
DMAQ vs HOLUU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HOLUU has a market cap of 3.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HOLUU trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HOLUU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to HOLUU's ROE of -0.13%. Regarding short-term risk, DMAQ is more volatile compared to HOLUU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HOLUU's competition here
Silver Spike Acquisition Corp. (NASDAQ: SSPK)
DMAQ vs SSPK Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SSPK has a market cap of 3.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SSPK trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SSPK's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SSPK's ROE of +0.03%. Regarding short-term risk, DMAQ is more volatile compared to SSPK. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SSPK's competition here
Falcon Capital Acquisition Corp. (NASDAQ: FCACU)
DMAQ vs FCACU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FCACU has a market cap of 3.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FCACU trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FCACU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FCACU's ROE of -0.00%. Regarding short-term risk, DMAQ is more volatile compared to FCACU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FCACU's competition here
CF Acquisition Corp. VI (NASDAQ: CFVI)
DMAQ vs CFVI Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CFVI has a market cap of 3.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CFVI trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CFVI's P/E ratio is -18.55. In terms of profitability, DMAQ's ROE is -3.18%, compared to CFVI's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to CFVI. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CFVI's competition here
Holicity Inc. (NASDAQ: HOL)
DMAQ vs HOL Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HOL has a market cap of 3.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HOL trades at $12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HOL's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to HOL's ROE of -0.13%. Regarding short-term risk, DMAQ is more volatile compared to HOL. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HOL's competition here
Tuscan Holdings Corp. (NASDAQ: THCB)
DMAQ vs THCB Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, THCB has a market cap of 3.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while THCB trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas THCB's P/E ratio is -81.30. In terms of profitability, DMAQ's ROE is -3.18%, compared to THCB's ROE of -0.23%. Regarding short-term risk, DMAQ is more volatile compared to THCB. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check THCB's competition here
Sustainable Opportunities Acquisition Corp. (NYSE: SOAC)
DMAQ vs SOAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SOAC has a market cap of 2.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SOAC trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SOAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SOAC's ROE of +3.51%. Regarding short-term risk, DMAQ is more volatile compared to SOAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SOAC's competition here
Decarbonization Plus Acquisition Corporation (NASDAQ: DCRBU)
DMAQ vs DCRBU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DCRBU has a market cap of 2.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DCRBU trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DCRBU's P/E ratio is -16.00. In terms of profitability, DMAQ's ROE is -3.18%, compared to DCRBU's ROE of -0.84%. Regarding short-term risk, DMAQ is more volatile compared to DCRBU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DCRBU's competition here
Ivanhoe Capital Acquisition Corp. (NYSE: IVAN)
DMAQ vs IVAN Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, IVAN has a market cap of 2.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while IVAN trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas IVAN's P/E ratio is -698.18. In terms of profitability, DMAQ's ROE is -3.18%, compared to IVAN's ROE of -0.32%. Regarding short-term risk, DMAQ is more volatile compared to IVAN. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check IVAN's competition here
Good Works Acquisition Corp. (NASDAQ: GWAC)
DMAQ vs GWAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GWAC has a market cap of 2.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GWAC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GWAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to GWAC's ROE of -1.56%. Regarding short-term risk, DMAQ is more volatile compared to GWAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GWAC's competition here
Landcadia Holdings III, Inc (NASDAQ: LCYAU)
DMAQ vs LCYAU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, LCYAU has a market cap of 2.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while LCYAU trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas LCYAU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to LCYAU's ROE of +0.04%. Regarding short-term risk, DMAQ is more volatile compared to LCYAU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check LCYAU's competition here
Fifth Wall Acquisition Corp. I (NASDAQ: FWAA)
DMAQ vs FWAA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FWAA has a market cap of 2.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FWAA trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FWAA's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FWAA's ROE of -0.11%. Regarding short-term risk, DMAQ is more volatile compared to FWAA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FWAA's competition here
GS Acquisition Holdings Corp II (NYSE: GSAH)
DMAQ vs GSAH Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GSAH has a market cap of 2.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GSAH trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GSAH's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to GSAH's ROE of +0.42%. Regarding short-term risk, DMAQ is more volatile compared to GSAH. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GSAH's competition here
Landcadia Holdings III, Inc (NASDAQ: LCY)
DMAQ vs LCY Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, LCY has a market cap of 2.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while LCY trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas LCY's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to LCY's ROE of +0.04%. Regarding short-term risk, DMAQ is more volatile compared to LCY. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check LCY's competition here
Foresight Acquisition Corp. (NASDAQ: FORE)
DMAQ vs FORE Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FORE has a market cap of 2.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FORE trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FORE's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FORE's ROE of +4.34%. Regarding short-term risk, DMAQ is more volatile compared to FORE. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FORE's competition here
Churchill Capital Corp XI Warrants (NASDAQ: CCXIW)
DMAQ vs CCXIW Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CCXIW has a market cap of 2.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CCXIW trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CCXIW's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to CCXIW's ROE of N/A. Regarding short-term risk, DMAQ is more volatile compared to CCXIW. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CCXIW's competition here
Revolution Acceleration Acquisition Corp (NASDAQ: RAAC)
DMAQ vs RAAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, RAAC has a market cap of 2.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while RAAC trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas RAAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to RAAC's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to RAAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check RAAC's competition here
Supernova Partners Acquisition Company, Inc. (NYSE: SPNV)
DMAQ vs SPNV Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SPNV has a market cap of 2.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SPNV trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SPNV's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SPNV's ROE of -1.12%. Regarding short-term risk, DMAQ is more volatile compared to SPNV. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SPNV's competition here
Social Capital Suvretta Holdings Corp. III (NASDAQ: DNAC)
DMAQ vs DNAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DNAC has a market cap of 2.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DNAC trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DNAC's P/E ratio is -37.72. In terms of profitability, DMAQ's ROE is -3.18%, compared to DNAC's ROE of -0.34%. Regarding short-term risk, DMAQ is more volatile compared to DNAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DNAC's competition here
Fortress Value Acquisition Corp. II (NYSE: FAII)
DMAQ vs FAII Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FAII has a market cap of 2.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FAII trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FAII's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FAII's ROE of -0.32%. Regarding short-term risk, DMAQ is more volatile compared to FAII. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FAII's competition here
dMY Technology Group, Inc. III (NYSE: DMYI)
DMAQ vs DMYI Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DMYI has a market cap of 2.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DMYI trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DMYI's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to DMYI's ROE of +0.11%. Regarding short-term risk, DMAQ is more volatile compared to DMYI. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DMYI's competition here
Live Oak Acquisition Corp. II (NYSE: LOKB)
DMAQ vs LOKB Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, LOKB has a market cap of 2.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while LOKB trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas LOKB's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to LOKB's ROE of -0.62%. Regarding short-term risk, DMAQ is more volatile compared to LOKB. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check LOKB's competition here
Star Peak Corp II (NYSE: STPC)
DMAQ vs STPC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, STPC has a market cap of 2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while STPC trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas STPC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to STPC's ROE of -0.29%. Regarding short-term risk, DMAQ is more volatile compared to STPC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check STPC's competition here
Mudrick Capital Acquisition Corporation II (NASDAQ: MUDS)
DMAQ vs MUDS Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, MUDS has a market cap of 2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while MUDS trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas MUDS's P/E ratio is 3.39. In terms of profitability, DMAQ's ROE is -3.18%, compared to MUDS's ROE of -0.01%. Regarding short-term risk, DMAQ is more volatile compared to MUDS. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check MUDS's competition here
Mudrick Capital Acquisition Corporation II (NASDAQ: MUDSU)
DMAQ vs MUDSU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, MUDSU has a market cap of 2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while MUDSU trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas MUDSU's P/E ratio is -1125.56. In terms of profitability, DMAQ's ROE is -3.18%, compared to MUDSU's ROE of -0.01%. Regarding short-term risk, DMAQ is more volatile compared to MUDSU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check MUDSU's competition here
Tiga Acquisition Corp. (NYSE: TINV)
DMAQ vs TINV Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, TINV has a market cap of 2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while TINV trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas TINV's P/E ratio is 30.61. In terms of profitability, DMAQ's ROE is -3.18%, compared to TINV's ROE of +1.23%. Regarding short-term risk, DMAQ is more volatile compared to TINV. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check TINV's competition here
Apex Treasury Corporation Class A (NASDAQ: APXT)
DMAQ vs APXT Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, APXT has a market cap of 1.9B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while APXT trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas APXT's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to APXT's ROE of +0.10%. Regarding short-term risk, DMAQ is more volatile compared to APXT. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check APXT's competition here
Apex Treasury Corporation (NASDAQ: APXTU)
DMAQ vs APXTU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, APXTU has a market cap of 1.9B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while APXTU trades at $10.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas APXTU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to APXTU's ROE of +0.10%. Regarding short-term risk, DMAQ is more volatile compared to APXTU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check APXTU's competition here
Digital World Acquisition Corp. (NASDAQ: DWAC)
DMAQ vs DWAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DWAC has a market cap of 1.9B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DWAC trades at $49.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DWAC's P/E ratio is -73.46. In terms of profitability, DMAQ's ROE is -3.18%, compared to DWAC's ROE of -0.58%. Regarding short-term risk, DMAQ is more volatile compared to DWAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DWAC's competition here
Digital World Acquisition Corp. (NASDAQ: DWACU)
DMAQ vs DWACU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DWACU has a market cap of 1.9B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DWACU trades at $61.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DWACU's P/E ratio is -451.10. In terms of profitability, DMAQ's ROE is -3.18%, compared to DWACU's ROE of -0.58%. Regarding short-term risk, DMAQ is more volatile compared to DWACU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DWACU's competition here
Athena Technology Acquisition Corp. (NYSE: ATHN)
DMAQ vs ATHN Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, ATHN has a market cap of 1.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while ATHN trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas ATHN's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to ATHN's ROE of +2.24%. Regarding short-term risk, DMAQ is more volatile compared to ATHN. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check ATHN's competition here
Gores Metropoulos II, Inc. (NASDAQ: GMII)
DMAQ vs GMII Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GMII has a market cap of 1.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GMII trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GMII's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to GMII's ROE of +0.21%. Regarding short-term risk, DMAQ is more volatile compared to GMII. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GMII's competition here
Apex Treasury Corporation (NASDAQ: APXTW)
DMAQ vs APXTW Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, APXTW has a market cap of 1.8B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while APXTW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas APXTW's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to APXTW's ROE of +0.10%. Regarding short-term risk, DMAQ is more volatile compared to APXTW. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check APXTW's competition here
Motive Capital Corp. (NYSE: MOTV)
DMAQ vs MOTV Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, MOTV has a market cap of 1.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while MOTV trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas MOTV's P/E ratio is 55.86. In terms of profitability, DMAQ's ROE is -3.18%, compared to MOTV's ROE of -0.23%. Regarding short-term risk, DMAQ is more volatile compared to MOTV. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check MOTV's competition here
CBRE Acquisition Holdings, Inc. (NYSE: CBAH)
DMAQ vs CBAH Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CBAH has a market cap of 1.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CBAH trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CBAH's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to CBAH's ROE of +0.04%. Regarding short-term risk, DMAQ is more volatile compared to CBAH. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CBAH's competition here
GX Acquisition Corp. (NASDAQ: GXGXU)
DMAQ vs GXGXU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GXGXU has a market cap of 1.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GXGXU trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GXGXU's P/E ratio is -23.73. In terms of profitability, DMAQ's ROE is -3.18%, compared to GXGXU's ROE of -0.03%. Regarding short-term risk, DMAQ is more volatile compared to GXGXU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GXGXU's competition here
One (NYSE: AONE)
DMAQ vs AONE Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, AONE has a market cap of 1.7B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while AONE trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas AONE's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to AONE's ROE of -17.11%. Regarding short-term risk, DMAQ is more volatile compared to AONE. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check AONE's competition here
Tortoise Acquisition Corp. II (NYSE: SNPR)
DMAQ vs SNPR Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SNPR has a market cap of 1.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SNPR trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SNPR's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SNPR's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to SNPR. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SNPR's competition here
Jaws Spitfire Acquisition Corporation (NYSE: SPFR)
DMAQ vs SPFR Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SPFR has a market cap of 1.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SPFR trades at $8.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SPFR's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SPFR's ROE of -4.58%. Regarding short-term risk, DMAQ is more volatile compared to SPFR. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SPFR's competition here
D8 Holdings Corp. (NYSE: DEH)
DMAQ vs DEH Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DEH has a market cap of 1.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DEH trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DEH's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to DEH's ROE of -3.33%. Regarding short-term risk, DMAQ is more volatile compared to DEH. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DEH's competition here
Rotor Acquisition Corp. (NYSE: ROT)
DMAQ vs ROT Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, ROT has a market cap of 1.6B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while ROT trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas ROT's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to ROT's ROE of -0.40%. Regarding short-term risk, DMAQ is more volatile compared to ROT. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check ROT's competition here
NextGen Acquisition Corporation (NASDAQ: NGAC)
DMAQ vs NGAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, NGAC has a market cap of 1.5B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while NGAC trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas NGAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to NGAC's ROE of -0.87%. Regarding short-term risk, DMAQ is more volatile compared to NGAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check NGAC's competition here
Celularity Inc. (NASDAQ: GXGX)
DMAQ vs GXGX Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, GXGX has a market cap of 1.5B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while GXGX trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas GXGX's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to GXGX's ROE of +4.12%. Regarding short-term risk, DMAQ is more volatile compared to GXGX. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check GXGX's competition here
Hudson Executive Investment Corp. (NASDAQ: HECCU)
DMAQ vs HECCU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HECCU has a market cap of 1.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HECCU trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HECCU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to HECCU's ROE of -0.09%. Regarding short-term risk, DMAQ is more volatile compared to HECCU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HECCU's competition here
Altimar Acquisition Corp. II (NYSE: ATMR)
DMAQ vs ATMR Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, ATMR has a market cap of 1.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while ATMR trades at $10.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas ATMR's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to ATMR's ROE of +0.44%. Regarding short-term risk, DMAQ is more volatile compared to ATMR. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check ATMR's competition here
Osprey Technology Acquisition Corp. (NYSE: SFTW)
DMAQ vs SFTW Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SFTW has a market cap of 1.4B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SFTW trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SFTW's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SFTW's ROE of -0.99%. Regarding short-term risk, DMAQ is more volatile compared to SFTW. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SFTW's competition here
890 5th Avenue Partners, Inc. (NASDAQ: ENFA)
DMAQ vs ENFA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, ENFA has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while ENFA trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas ENFA's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to ENFA's ROE of -0.99%. Regarding short-term risk, DMAQ is more volatile compared to ENFA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check ENFA's competition here
Environmental Impact Acquisition Corp. (NASDAQ: ENVI)
DMAQ vs ENVI Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, ENVI has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while ENVI trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas ENVI's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to ENVI's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to ENVI. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check ENVI's competition here
ArcLight Clean Transition Corp. II (NASDAQ: ACTD)
DMAQ vs ACTD Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, ACTD has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while ACTD trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas ACTD's P/E ratio is -25.50. In terms of profitability, DMAQ's ROE is -3.18%, compared to ACTD's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to ACTD. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check ACTD's competition here
Vickers Vantage Corp. I (NASDAQ: VCKA)
DMAQ vs VCKA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, VCKA has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while VCKA trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas VCKA's P/E ratio is 100.11. In terms of profitability, DMAQ's ROE is -3.18%, compared to VCKA's ROE of +1.68%. Regarding short-term risk, DMAQ is more volatile compared to VCKA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check VCKA's competition here
Thimble Point Acquisition Corp. (NASDAQ: THMA)
DMAQ vs THMA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, THMA has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while THMA trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas THMA's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to THMA's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to THMA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check THMA's competition here
L&F Acquisition Corp. (NYSE: LNFA)
DMAQ vs LNFA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, LNFA has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while LNFA trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas LNFA's P/E ratio is 21.06. In terms of profitability, DMAQ's ROE is -3.18%, compared to LNFA's ROE of +0.09%. Regarding short-term risk, DMAQ is more volatile compared to LNFA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check LNFA's competition here
Fintech Acquisition Corp. IV (NASDAQ: FTIVU)
DMAQ vs FTIVU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FTIVU has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FTIVU trades at $14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FTIVU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FTIVU's ROE of -0.09%. Regarding short-term risk, DMAQ is more volatile compared to FTIVU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FTIVU's competition here
ACON S2 Acquisition Corp. (NASDAQ: STWO)
DMAQ vs STWO Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, STWO has a market cap of 1.3B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while STWO trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas STWO's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to STWO's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to STWO. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check STWO's competition here
Haymaker Acquisition Corp. III (NASDAQ: HYACU)
DMAQ vs HYACU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HYACU has a market cap of 1.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HYACU trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HYACU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to HYACU's ROE of -0.01%. Regarding short-term risk, DMAQ is more volatile compared to HYACU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HYACU's competition here
Fintech Acquisition Corp. IV (NASDAQ: FTIV)
DMAQ vs FTIV Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FTIV has a market cap of 1.2B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FTIV trades at $13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FTIV's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FTIV's ROE of -0.09%. Regarding short-term risk, DMAQ is more volatile compared to FTIV. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FTIV's competition here
Alpha Healthcare Acquisition Corp. (NASDAQ: AHAC)
DMAQ vs AHAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, AHAC has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while AHAC trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas AHAC's P/E ratio is -72.11. In terms of profitability, DMAQ's ROE is -3.18%, compared to AHAC's ROE of -16.18%. Regarding short-term risk, DMAQ is more volatile compared to AHAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check AHAC's competition here
Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC)
DMAQ vs AMHC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, AMHC has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while AMHC trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas AMHC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to AMHC's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to AMHC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check AMHC's competition here
FTAC Hera Acquisition Corp. (NASDAQ: HERAW)
DMAQ vs HERAW Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HERAW has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HERAW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HERAW's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to HERAW's ROE of +0.01%. Regarding short-term risk, DMAQ is more volatile compared to HERAW. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HERAW's competition here
FTAC Hera Acquisition Corp. (NASDAQ: HERA)
DMAQ vs HERA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HERA has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HERA trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HERA's P/E ratio is 46.32. In terms of profitability, DMAQ's ROE is -3.18%, compared to HERA's ROE of +0.01%. Regarding short-term risk, DMAQ is more volatile compared to HERA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HERA's competition here
FG New America Acquisition Corp. (NYSE: FGNA)
DMAQ vs FGNA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FGNA has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FGNA trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FGNA's P/E ratio is -4.35. In terms of profitability, DMAQ's ROE is -3.18%, compared to FGNA's ROE of +0.71%. Regarding short-term risk, DMAQ is more volatile compared to FGNA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FGNA's competition here
Social Capital Suvretta Holdings Corp. I (NASDAQ: DNAA)
DMAQ vs DNAA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, DNAA has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while DNAA trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas DNAA's P/E ratio is -54.53. In terms of profitability, DMAQ's ROE is -3.18%, compared to DNAA's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to DNAA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check DNAA's competition here
Therapeutics Acquisition Corp. (NASDAQ: RACA)
DMAQ vs RACA Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, RACA has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while RACA trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas RACA's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to RACA's ROE of +0.00%. Regarding short-term risk, DMAQ is more volatile compared to RACA. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check RACA's competition here
Trebia Acquisition Corp. (NYSE: TREB)
DMAQ vs TREB Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, TREB has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while TREB trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas TREB's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to TREB's ROE of -3.33%. Regarding short-term risk, DMAQ is more volatile compared to TREB. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check TREB's competition here
TPG Pace Tech Opportunities Corp. (NYSE: PACE)
DMAQ vs PACE Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, PACE has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while PACE trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas PACE's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to PACE's ROE of -1.42%. Regarding short-term risk, DMAQ is more volatile compared to PACE. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check PACE's competition here
FTAC Hera Acquisition Corp. (NASDAQ: HERAU)
DMAQ vs HERAU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, HERAU has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while HERAU trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas HERAU's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to HERAU's ROE of +0.01%. Regarding short-term risk, DMAQ is more volatile compared to HERAU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check HERAU's competition here
LifeSci Acquisition II Corp. (NASDAQ: LSAQ)
DMAQ vs LSAQ Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, LSAQ has a market cap of 1.1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while LSAQ trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas LSAQ's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to LSAQ's ROE of N/A. Regarding short-term risk, DMAQ is more volatile compared to LSAQ. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check LSAQ's competition here
Stable Road Acquisition Corp. (NASDAQ: SRAC)
DMAQ vs SRAC Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SRAC has a market cap of 1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SRAC trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SRAC's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SRAC's ROE of -4.03%. Regarding short-term risk, DMAQ is more volatile compared to SRAC. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SRAC's competition here
FTAC Parnassus Acquisition Corp. (NASDAQ: FTPAW)
DMAQ vs FTPAW Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, FTPAW has a market cap of 1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while FTPAW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas FTPAW's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to FTPAW's ROE of -0.00%. Regarding short-term risk, DMAQ is more volatile compared to FTPAW. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check FTPAW's competition here
Sandbridge Acquisition Corporation (NYSE: SBG)
DMAQ vs SBG Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, SBG has a market cap of 1B. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while SBG trades at $8.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas SBG's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to SBG's ROE of -3.15%. Regarding short-term risk, DMAQ is more volatile compared to SBG. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check SBG's competition here
Churchill Capital Corp VII (NYSE: CVII-WT)
DMAQ vs CVII-WT Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CVII-WT has a market cap of 977.9M. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CVII-WT trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CVII-WT's P/E ratio is N/A. In terms of profitability, DMAQ's ROE is -3.18%, compared to CVII-WT's ROE of +0.02%. Regarding short-term risk, DMAQ is more volatile compared to CVII-WT. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CVII-WT's competition here
Churchill Capital Corp VII (NYSE: CVII-UN)
DMAQ vs CVII-UN Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CVII-UN has a market cap of 958.8M. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CVII-UN trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CVII-UN's P/E ratio is 64.65. In terms of profitability, DMAQ's ROE is -3.18%, compared to CVII-UN's ROE of +0.02%. Regarding short-term risk, DMAQ is more volatile compared to CVII-UN. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CVII-UN's competition here
B. Riley Principal 150 Merger Corp. (NASDAQ: BRPM)
DMAQ vs BRPM Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, BRPM has a market cap of 944M. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while BRPM trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas BRPM's P/E ratio is -72.74. In terms of profitability, DMAQ's ROE is -3.18%, compared to BRPM's ROE of -32.54%. Regarding short-term risk, DMAQ is more volatile compared to BRPM. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check BRPM's competition here
Crescent Acquisition Corp. (NASDAQ: CRSAU)
DMAQ vs CRSAU Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CRSAU has a market cap of 937.8M. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CRSAU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CRSAU's P/E ratio is -27.21. In terms of profitability, DMAQ's ROE is -3.18%, compared to CRSAU's ROE of -0.34%. Regarding short-term risk, DMAQ is more volatile compared to CRSAU. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CRSAU's competition here
Churchill Capital Corp VII (NYSE: CVII)
DMAQ vs CVII Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, CVII has a market cap of 914.7M. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while CVII trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas CVII's P/E ratio is 999.00. In terms of profitability, DMAQ's ROE is -3.18%, compared to CVII's ROE of +0.02%. Regarding short-term risk, DMAQ is more volatile compared to CVII. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check CVII's competition here
BCTG Acquisition Corp. (NASDAQ: BCTG)
DMAQ vs BCTG Comparison July 2026
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMAQ stands at 12.9M. In comparison, BCTG has a market cap of 899.4M. Regarding current trading prices, DMAQ is priced at $2.96 on the NASDAQ, while BCTG trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMAQ currently has a P/E ratio of -22.77, whereas BCTG's P/E ratio is -204.00. In terms of profitability, DMAQ's ROE is -3.18%, compared to BCTG's ROE of -0.42%. Regarding short-term risk, DMAQ is more volatile compared to BCTG. This indicates higher risk in terms of short-term price fluctuations for DMAQ.Check BCTG's competition here